{"contentid": 488187, "importid": NaN, "name": "Samsung Bioepis continues roll out of biosimilar Hadlima", "introduction": "South Korea\u00e2\u0080\u0099s Samsung Bioepis says it is expanding its global footprint to Australia with the launch of Hadlima (adalimumab), a biosimilar referencing AbbVie\u00e2\u0080\u0099s (NYSE: ABBV) mega-billion drug Humira.", "content": "<p>South Korea&rsquo;s Samsung Bioepis says it is expanding its global footprint to Australia with the launch of Hadlima (adalimumab), a biosimilar referencing AbbVie&rsquo;s (NYSE: ABBV) mega-billion drug Humira, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn&rsquo;s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.</p>\n<p>With the launch in Australia, Samsung Bioepis&rsquo; adalimumab is now available in three markets: Europe, Canada and Australia, underscoring the company&rsquo;s continuous efforts to expand its reach in multiple markets across the world. It was first launched in Europe in October 2018 under the name Imraldi in partnership with Biogen (Nasdaq: BIIB), followed by Canada in February 2021 in partnership with Merck &amp; Co (NYSE: MRK), known as MSD outside of the USA and Canada.</p>\n<p>&ldquo;We are delighted by our partnership with MSD Australia to bring this important medicine to patients in Australia, followed by our recent launch in Canada,&rdquo; said Albert Kim, vice president of the commercial strategy team at Samsung Bioepis, a joint venture involving Samsung BioLogics and US biotech Biogen, adding: &ldquo;It marks another important milestone for us and represents our commitment to bring high quality treatment to patients around the world.&rdquo;</p>\n<h2><strong>Will be available on PBS in April</strong></h2>\n<p>Hadlima is Samsung Bioepis&rsquo; third anti-TNF biosimilar launched in Australia, following the launch of Brenzys (etanercept) in December 2016 and Renflexis (infliximab) in July 2017. Hadlima will be available on the Pharmaceutical Benefits Scheme (PBS) from April 1, 2021.</p>\n<p>In addition to Australia and Canada, Samsung Bioepis&rsquo; adalimumab has obtained approval for marketing its biosimilar in Europe, Switzerland, the USA and Korea. However, under an agreement with AbbVie, the biosimilar cannot be launched in the USA until 2023.</p>\n<p>Samsung Bioepis partnered with Merck &amp; Co in 2013. Under terms of the agreement, Samsung Bioepis is responsible for pre-clinical and clinical development, process development, manufacturing, clinical trials and regulatory registration, while Merck is responsible for commercialization of the products approved in its partnered territories.</p>", "date": "2021-03-29 15:52:00", "meta_title": "Samsung Bioepis continues roll out of biosimilar Hadlima", "meta_keywords": "Samsung Bioepis, Biosimilar, Humira, Hadlima, Launch, AbbVie, MSD Australia", "meta_description": "Samsung Bioepis continues roll out of biosimilar Hadlima", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-29 15:51:37", "updated": "2021-03-29 16:00:11", "access": NaN, "url": "https://www.thepharmaletter.com/article/samsung-bioepis-continues-roll-out-of-biosimilar-hadlima", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "samsung_bioepis_new_headquarters_large.jpg", "image2id": "samsung_bioepis_new_headquarters_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars", "therapy area_tag": "Anti-Arthritics/Rheumatics, Dermatologicals, Gastroenterology", "topic_tag": "Product Launch", "geography_tag": "Australia, South Korea", "company_tag": "AbbVie, Samsung Bioepis", "drug_tag": "Hadlima, Humira", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-29 15:52:00"}